The adrenogenital syndrome treatment market is projected to grow from USD 14.2 billion in 2025 to USD 24.5 billion by 2035, at a CAGR of 5.6%. Mineralocorticoids will dominate with a 54.7% market share, while oral will lead the route of administration segment with a 48.9% share.